- Home
- MDCX vs CGTX Comparison
MDCX vs CGTX Comparison
Compare MDCX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- CGTX
- Stock Information
- Founded
- MDCX 2008
- CGTX 2007
- Country
- MDCX Canada
- CGTX United States
- Employees
- MDCX N/A
- CGTX N/A
- Industry
- MDCX
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MDCX
- CGTX Health Care
- Exchange
- MDCX Nasdaq
- CGTX Nasdaq
- Market Cap
- MDCX 44.0M
- CGTX 20.5M
- IPO Year
- MDCX N/A
- CGTX 2021
- Fundamental
- Price
- MDCX $3.18
- CGTX $0.30
- Analyst Decision
- MDCX Strong Buy
- CGTX Strong Buy
- Analyst Count
- MDCX 2
- CGTX 5
- Target Price
- MDCX $23.50
- CGTX $5.63
- AVG Volume (30 Days)
- MDCX 304.1K
- CGTX 1.9M
- Earning Date
- MDCX 08-22-2025
- CGTX 08-07-2025
- Dividend Yield
- MDCX N/A
- CGTX N/A
- EPS Growth
- MDCX N/A
- CGTX N/A
- EPS
- MDCX N/A
- CGTX N/A
- Revenue
- MDCX N/A
- CGTX N/A
- Revenue This Year
- MDCX N/A
- CGTX N/A
- Revenue Next Year
- MDCX N/A
- CGTX N/A
- P/E Ratio
- MDCX N/A
- CGTX N/A
- Revenue Growth
- MDCX N/A
- CGTX N/A
- 52 Week Low
- MDCX $1.80
- CGTX $0.22
- 52 Week High
- MDCX $8.94
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- MDCX N/A
- CGTX 48.87
- Support Level
- MDCX N/A
- CGTX $0.25
- Resistance Level
- MDCX N/A
- CGTX $0.33
- Average True Range (ATR)
- MDCX 0.00
- CGTX 0.03
- MACD
- MDCX 0.00
- CGTX 0.00
- Stochastic Oscillator
- MDCX 0.00
- CGTX 58.69
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.